Latest Breaking News On - ஷரன் ஸிட்ஹு - Page 1 : comparemela.com
Numinus Files U S Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Numinus Wellness Inc files US patent application for its proprietary rapid psilocybin production process
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
The initial trial would focus on dosage before expanding into psilocybin treatments for a variety of health conditions.
“This is another important step for our commitment to the development of naturally sourced, evidence-based product formulations,” said Optimi chairman of the board JJ Wilson.
The information package included the investigational product’s chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from psilocybe mushrooms.
Optimi will retain 100 per cent ownership of the resulting all-natural psilocybin capsule and full intellectual property rights to its use, according to the release.
“Numinus is pleased to partner with Optimi on this important work and provide the expertise, licensed facility and specialized equipment required to quickly develop, formulate and rigorously test products derived from natural psilocybe sources and prepare them for Health Canada submissions and approvals,” said Sharan
Numinus Wellness and Optimi Health submit evidence package to Health Canada for all-natural psilocybin extract
Numinus plans to use the candidate mushroom clone to develop a uniform all-natural psilocybin capsule for use in Optimi s human clinical trials Studies are also ongoing at the Numinus lab in British Columbia
Numinus Wellness Inc (CVE:NUMI) said it has submitted a pre-clinical trial application to Health Canada for review of its all-natural psilocybin extract.
The Vancouver-based psychedelics company has partnered with Optimi Health Corp (CSE:OPTI) (OTCMKTS:OPTHF) to develop the psilocybin extract through Impact Clinical Trials Accelerator at the University of Calgary.
Sairiyo Therapeutics Inc., for the use of DMT in organ transplantations.
When patients undergo an organ transplant, there s a high risk of ischemia-reperfusion injury, a type of injury that can occur when blood rapidly returns to the organ after being restricted by a long period. This can lead to the organ being rejected by the body, as well as other injuries to the patient.
Preclinical models of kidney transplantation showed that DMT can be used to mitigate injury caused by ischemia-reperfusion. The treatment still needs to undergo extensive clinical research.
“We are the first and only company in the world to receive FDA orphan drug designation for DMT,” said Daniel Cohen, CEO of PharmaDrug.
vimarsana © 2020. All Rights Reserved.